ER&D services largest pure-play, Alten, has ambitions as a clinical trials contract research organization (CRO). During Q2 2021, the company completed the acquisition of Cmed. Cmed, a clinical trial CRO based in the UK. It is a small firm with EUR 20m in revenues and 180 consultants. It has specialized in oncology, immuno-oncology, cell therapy, and rare disease.
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org.
Icon made a step change in the clinical trials CRO market with its USD 12bn planned PRA Health Sciences acquisition. The purpose of the transaction is scale. With PRA Health Services, Icon will double its size.
Charles River Labs (CRL) will gain further expertise for biotechs. The company is to acquire San Francisco-based Distributed Bio, a large molecules specialist firm focusing on antibody discovery. Distributed Bio will become part of CRL’s core R&D business, Discovery & Safety Assessment.
In August, CRL acquired a small firm, Cellero, headquartered close to Boston for USD 38m. Cellero brought a geography presence to HEMA (which is based in California).
Oncodesign has restructured its business into three distinct business units (BU): Service, Biotech, and AI. Each BU will have its own objectives and delivery organization.
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org.
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org